Literature DB >> 28562256

Sporadic Insulinoma Presenting as Early Morning Night Terrors.

Daniel Beisang1, Gregory P Forlenza1,2, Mark Luquette3, Kyriakie Sarafoglou4.   

Abstract

A 16-year-old boy with a recent diagnosis of night terrors was evaluated for recurrent early morning hypoglycemia after an early morning seizure. Evaluation in clinic with critical laboratories identified hyperinsulinemic hypoglycemia. Additional investigation revealed a sporadic insulinoma as the etiology of his hypoglycemia and all symptoms were resolved after pancreaticoduodenectomy. The importance of obtaining critical laboratory samples is highlighted and appropriate radiologic, medical, and pathologic testing is discussed. We additionally review the medical and surgical management of hyperinsulinemic hypoglycemia. A discussion of multiple endocrine neoplasia type 1 associated insulinomas is included as well. This case highlights the importance of considering hypoglycemia in the evaluation of night terrors and new-onset seizures.
Copyright © 2017 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28562256      PMCID: PMC5996761          DOI: 10.1542/peds.2016-2007

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  20 in total

Review 1.  Mechanisms of hypoglycemia-associated autonomic failure in diabetes.

Authors:  Philip E Cryer
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

2.  Diazoxide in the management of patients with insulinoma.

Authors:  P N Goode; J R Farndon; J Anderson; I D Johnston; J A Morte
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

3.  Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections.

Authors:  Stefano Crippa; Alessandro Zerbi; Letizia Boninsegna; Vanessa Capitanio; Stefano Partelli; Gianpaolo Balzano; Paolo Pederzoli; Valerio Di Carlo; Massimo Falconi
Journal:  Arch Surg       Date:  2012-03

4.  Neuroglycopenic and other symptoms in patients with insulinomas.

Authors:  A M Dizon; S Kowalyk; B J Hoogwerf
Journal:  Am J Med       Date:  1999-03       Impact factor: 4.965

5.  Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans.

Authors:  Natalia S Pellegata; Leticia Quintanilla-Martinez; Heide Siggelkow; Elenore Samson; Karin Bink; Heinz Höfler; Falko Fend; Jochen Graw; Michael J Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-09       Impact factor: 11.205

Review 6.  Hypoglycemia unawareness.

Authors:  J E Gerich; M Mokan; T Veneman; M Korytkowski; A Mitrakou
Journal:  Endocr Rev       Date:  1991-11       Impact factor: 19.871

Review 7.  The management of insulinoma.

Authors:  O N Tucker; P L Crotty; K C Conlon
Journal:  Br J Surg       Date:  2006-03       Impact factor: 6.939

8.  Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations.

Authors:  Susana Igreja; Harvinder S Chahal; Scott A Akker; Maria Gueorguiev; Vera Popovic; Svetozar Damjanovic; Pia Burman; John A Wass; Richard Quinton; Ashley B Grossman; Márta Korbonits
Journal:  Clin Endocrinol (Oxf)       Date:  2008-08-15       Impact factor: 3.478

9.  Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children.

Authors:  Paul S Thornton; Charles A Stanley; Diva D De Leon; Deborah Harris; Morey W Haymond; Khalid Hussain; Lynne L Levitsky; Mohammad H Murad; Paul J Rozance; Rebecca A Simmons; Mark A Sperling; David A Weinstein; Neil H White; Joseph I Wolfsdorf
Journal:  J Pediatr       Date:  2015-05-06       Impact factor: 4.406

10.  Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors.

Authors:  F Gibril; R T Jensen
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.